University of Münster

Running trials

• Not yet recruiting

  Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR

  2024-517295-37-00· PHASE3· Source

• Not yet recruiting

  A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)

  2026-525757-37-00· PHASE3· Source

• Not yet recruiting

  A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)

  2026-525755-82-00· PHASE3· Source

• Not yet recruiting

  A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis

  NCT07873801· PHASE3· Source

• Not yet recruiting

  Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

  NCT07781657· PHASE2· Source

• Recruiting

  A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma.

  2025-525030-57-00· PHASE3· Source

• Not yet recruiting

  Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease

  NCT07781644· PHASE1 PHASE2· Source

• Not yet recruiting

  A study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis

  2026-526184-38-00· PHASE2· Source

• Recruiting

  Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  NCT07711002· PHASE3· Source

• Recruiting

  A Phase 2b Study of the Effects of Camoteskimab in Adults with Moderate-to-Severe Atopic Dermatitis

  2026-525673-39-00· PHASE2· Source

• Not yet recruiting

  Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Benefited from Continued Treatment.

  2026-526419-13-00· PHASE3· Source

• Not yet recruiting

  AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

  2025-522190-11-01· PHASE3· Source

• Recruiting

  A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder.

  2025-524488-18-00· PHASE2· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· PHASE3· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· PHASE3· Source

• Not yet recruiting

  A double-blind, randomised, placebo-controlled, first-in-human (FIH) Phase I/IIa, multi-centre trial to assess safety, tolerability, and immune response of single and multiple ascending doses of TOL2 (Immune Tolerising Agent) in patients with generalised myasthenia gravis

  2024-515627-10-00· PHASE1 PHASE2· Source

• Recruiting

  A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

  NCT07419295· PHASE3· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· PHASE3· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

  NCT07225270· PHASE3· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· PHASE3· Source

• Recruiting

  A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07287150· PHASE2· Source

• Recruiting

  Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants

  2025-521762-99-00· PHASE3· Source

• Recruiting

  A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

  NCT07409272· PHASE3· Source

• Recruiting

  TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

  NCT07223203· PHASE3· Source

• Recruiting

  Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

  NCT07441395· PHASE2· Source

• Recruiting

  Neoadjuvant Darovasertib in Primary Uveal Melanoma

  NCT07015190· PHASE3· Source

• Recruiting

  A Study in Adults with Parkinson's Disease and a Lack of Interest or Motivation to Test How Different Doses of IRL757 Given for Multiple Days are Tolerated in the Body

  2025-523612-37-00· PHASE1· Source

• Active, not recruiting

  A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

  NCT07230860· PHASE2· Source

• Recruiting

  Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

  NCT07217587· PHASE3· Source

• Recruiting

  Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.

  2024-512503-39-00· PHASE4· Source

• Recruiting

  A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

  NCT07221188· PHASE3· Source

• Recruiting

  A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

  NCT07250802· PHASE3· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

  NCT06979453· PHASE3· Source

• Recruiting

  A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

  NCT06807281· PHASE3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

  NCT07174310· PHASE3· Source

• Active, not recruiting

  A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

  NCT07217015· PHASE2· Source

• Recruiting

  Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE

  NCT05293080· PHASE3· Source

• Recruiting

  Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

  NCT07007065· PHASE3· Source

• Recruiting

  Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

  NCT07197307· PHASE2· Source

• Recruiting

  Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC

  NCT07026474· PHASE3· Source

• Recruiting

  Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease

  NCT07151378· PHASE3· Source

• Recruiting

  A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

  NCT07223021· PHASE3· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)

  2024-516652-18-00· PHASE3· Source

• Recruiting

  Long-term follow-up of patients treated with GD2IL18CART

  2025-521497-34-00· PHASE1· Source

• Recruiting

  A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis

  2024-519795-11-00· PHASE2· Source

• Recruiting

  HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

  NCT05751044· PHASE1 PHASE2· Source

• Recruiting

  HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

  NCT05745714· PHASE1 PHASE2· Source

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· PHASE3· Source

• Recruiting

  Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

  NCT07116967· PHASE3· Source

• Recruiting

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· PHASE3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers19 recruiting
• Acute lymphoblastic leukaemia9 recruiting
• Atopic dermatitis (eczema)8 recruiting
• Prostate cancer7 recruiting
• Acute myeloid leukemia5 recruiting
• Bladder cancer5 recruiting
• Fatty liver disease (MASLD/MASH)5 recruiting
• Lung cancer5 recruiting
• Metastatic breast cancer5 recruiting
• Parkinson disease5 recruiting
• Psoriasis5 recruiting
• Sarcoma5 recruiting
• Diffuse large B-cell lymphoma4 recruiting
• Endometrial cancer4 recruiting
• Neuroblastoma4 recruiting
• Ovarian cancer4 recruiting
• Colorectal cancer3 recruiting
• Follicular lymphoma3 recruiting
• Liver and biliary tract cancer3 recruiting
• Macular degeneration3 recruiting
• Myelodysplastic syndromes3 recruiting
• Pancreatic cancer3 recruiting
• Alzheimer disease2 recruiting
• Gastric and esophageal cancer2 recruiting
• Head and neck cancer2 recruiting
• Hodgkin lymphoma2 recruiting
• Melanoma2 recruiting
• Multiple sclerosis2 recruiting
• Myasthenia gravis2 recruiting
• Stroke2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Triple-negative breast cancer2 recruiting
• Amyloidosis1 recruiting
• Atrial fibrillation1 recruiting
• Cervical cancer1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Glioblastoma1 recruiting
• Lupus (SLE)1 recruiting
• Neuroendocrine tumours1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

  NCT07630974· PHASE1 PHASE2· Source

• Recruiting

  A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease

  2024-516966-12-00· PHASE2· Source

• Completed

  A Study Evaluating BFB759 in Atopic Dermatitis

  2025-521624-30-00· PHASE2· Source

• Completed

  GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease.

  2025-521107-42-00· PHASE2· Source

• Active, not recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

  NCT06744920· PHASE3· Source

• Completed

  A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia

  2024-511057-22-00· PHASE3· Source

• Completed

  Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

  NCT06433219· PHASE2· Source

• Completed

  A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06602219· PHASE2· Source

• Completed

  A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

  NCT06588738· PHASE3· Source

• Completed

  A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

  NCT06383403· PHASE3· Source

• Completed

  “A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis”

  2023-503289-22-00· PHASE2· Source

• Completed

  Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis

  NCT06430671· PHASE1· Source

• Completed

  A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy

  2023-506696-10-00· PHASE3· Source

• Completed

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis

  2023-506655-19-00· PHASE2· Source

• Completed

  A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

  NCT06333860· PHASE4· Source

• Completed

  EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE

  NCT06079190· PHASE2· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

  NCT06088043· PHASE3· Source

• Completed

  Cardiac safety of treosulfan chemotherapy prior to stem cell transplantation in patients with leukemia.

  2024-517377-24-00· PHASE1· Source

• Active, not recruiting

  IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

  NCT05155254· PHASE3· Source

• Active, not recruiting

  A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

  NCT05374512· PHASE3· Source

• Active, not recruiting

  Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

  NCT05201638· PHASE3· Source

• Active, not recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

  NCT05134441· PHASE3· Source

• Completed

  Evaluation of the feasibility of PD L 506 for stereotactic interstitial photodynamic therapy (iPDT) in adult patients with newly diagnosed supratentorial IDH wild-type glioblastoma

  NCT03897491· PHASE2· Source

• Completed

  An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)

  NCT04941768· Source

• Completed

  Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1)

  NCT04797780· PHASE3· Source

• Completed

  Study of Orally Administered CA-4948(IRAK4i) as a Monotherapy in patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome

  NCT04278768· PHASE1 PHASE2· Source

• Completed

  Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Brain Tumors

  NCT04738162· PHASE2· Source

• Completed

  Open Label 2-Arm Study of Venetoclax in Combination with Azacitidine Versus Best Supportive Care after Allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML)

  NCT04161885· PHASE3· Source

• Completed

  Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)

  NCT04330820· PHASE1 PHASE2· Source

• Completed

  Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

  NCT04318938· PHASE2· Source

• Active, not recruiting

  IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

  NCT04086264· PHASE1 PHASE2· Source

• Completed

  MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse

  NCT03769532· PHASE2· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· PHASE3· Source

• Completed

  A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

  NCT03952559· PHASE3· Source

• Completed

  Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma

  NCT03341520· PHASE2· Source

• Completed

  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822· PHASE3· Source

• Completed

  Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC

  NCT03075423· PHASE2· Source

• Completed

  Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)

  NCT02853331· PHASE3· Source

• Completed

  autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial

  2024-511235-10-00· PHASE3· Source

Trial sites

• Universitaet Muenster178 trials
• Universitaet Muenster0 trials
• Universität Münster0 trials
• University of Muenster3 trials
• University of Munster1 trial
• Westfälische Wilhelms-Universität Münster2 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Depression149 works · 1 trials
• Schizophrenia101 works · 0 trials
• Bipolar disorder91 works · 0 trials
• Multiple sclerosis75 works · 10 trials
• Neuromyelitis optica (NMOSD)9 works · 0 trials
• Pompe disease3 works · 0 trials
• CIDP (chronic inflammatory demyelinating polyneuropathy)2 works · 1 trials